Back to search
FDAFDA · Food and drugs·Recall number D-1507-2020

Elitek (rasburicase) for injection, 7.5 mg vial, Rx Only Mfd. by Sanofi - Aventis U. S. LLC Bridgewater, NJ, 08807, NDC 0024-5151-75

Published August 26, 2020 · Recall initiated: August 10, 2020

Summary

FDA records drug Class II recall D-1507-2020, published August 26, 2020 and initiated August 10, 2020. Recalling firm: Sanofi-Aventis U.S. LLC; Status: Ongoing; Reported quantity: 7451 vials; Lot: Lot #: A9306, Exp 2/28/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if ELITEK has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ELITEK
Manufacturer
Sanofi-Aventis U.S. LLC
Distributor
Nationwide in the US
Lot
Lot #: A9306, Exp 2/28/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Elitek (rasburicase) for injection, 7.5 mg vial, Rx Only Mfd. by Sanofi - Aventis U. S. LLC Bridgewater, NJ, 08807, NDC 0024-5151-75 recalled?

Yes. FDA published recall D-1507-2020 on August 26, 2020. Reported hazard: Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ELITEK.